Keimyung University announced Tuesday that a joint research team has developed a technology called "bioPhosTAC" (biological Phosphorylation Targeting Chimera), which selectively removes specific phosphorylation signals from target proteins. The team was led by professor Kwon Taek-gyu of Keimyung University's College of Medicine and professor Park Kwang-su of its College of Pharmacy, together with professor Shin Dong-hyuk of Yonsei University's Department of Life Sciences.
The team's findings were published in the international journal Advanced Science.
The paper, titled "Selective Modulation of OTUB1 Noncanonical Function via a bioPhosTAC Strategy," appeared in a journal with an impact factor of 14.1. The journal ranks in the top 10 percent, or Q1, of its field according to the Journal Citation Reports.
Dr. Seo Seung-eon and Dr. Woo Sun-min of Keimyung University, along with Choi Min-hyeong, a student at Yonsei University, took part as co-first authors of the study.
"While conventional drugs have focused on which kinase to inhibit, bioPhosTAC introduces a new approach that instead selects which protein's phosphorylation signal to remove," Kwon said. He added that the technology "has the potential to develop into a next-generation precision treatment strategy that can enhance therapeutic effects while reducing side effects."
"Because bioPhosTAC has a modular structure, it can be expanded and applied to a wide range of disease-related proteins," Park said, adding that it "will be used as a platform for precision medicine-based drug development."
"We have demonstrated the potential of a strategy that goes beyond existing technologies that remove the protein itself, instead regulating only specific signals," Shin explained. He said the work "lays the groundwork for a technology that could lead to next-generation cancer treatments."
kbj7653@heraldcorp.com
